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Sex differences in the agreement
between left ventricular ejection fraction
measured by myocardial perfusion
scintigraphy and by echocardiography
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Abstract
Background: Left ventricular ejection fraction (LVEF) is generally measured by echocardiography but is increasingly
available with myocardial perfusion scintigraphy. With myocardial perfusion scintigraphy, the threshold of LVEF below
which there is a risk for myocardial infarct or sudden cardiac death is higher for women (51%) than for men (43%). We
tested the hypothesis that such a sex difference may also occur with echocardiography and myocardial perfusion
scintigraphy.
Methods: Four hundred and four men, mean age¼ 67.7 SD¼ 12.3 yr; 339 women, 67.7 11.7 yr had separate
myocardial perfusion scintigraphy and echocardiography examinations within sixmonths. A subset of 327 of these
patients (181 men, 68.8 12.1 yr; 146 women, 66.4 12.1 yr) had examinations within onemonth and were additionally
analysed as this sub-group. Myocardial perfusion scintigraphy and echocardiography were used to measure LVEF at rest
and their agreement (neither considered as a reference method) was assessed by Bland–Altman plots: LVEF difference
(myocardial perfusion scintigraphy minus echocardiography ) against average LVEF (MPSþEcho
2
).
Results: Of patients who had myocardial perfusion scintigraphy and echocardiography performed within sixmonths,
mean LVEF difference¼þ1.1% (95% limits of agreement: 19.3 to þ21.6) in men but þ10.9% (10.7 to þ32.5) in
women. LVEF difference diverged from zero marginally in men (mean difference¼þ1.1, 95%CI ¼þ0.1 to þ2.1,
p¼ 0.028) but more in women (þ10.9, þ9.8 to þ12.1, p< 0.001). The LVEF difference correlated with average
LVEF itself in both men (r¼ 0.305, p< 0.001) and women (r¼ 0.361, p< 0.001), and with age in women (r¼ 0.117,
p¼ 0.031). Similar results were observed for the subset.
Conclusions: Caution should be taken when interpreting LVEF measured by different techniques due to their wide
limits of agreement and systematic bias, more markedly in women.
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Introduction
Left ventricular ejection fraction (LVEF) is routinely
used in clinical practice for diagnostic, prognostic and
therapeutic procedures to measure left ventricular func-
tion1–4 and is useful to evaluate responses to treatment
in clinical trials.5 Several non-invasive methods are
used to estimate LVEF and because of its low cost,
availability and operational ease, echocardiography
(Echo) is the most common. However, LVEF estimates
are increasingly provided by other methods such as
myocardial perfusion scintigraphy (MPS), computed
tomography and cardiovascular magnetic
resonance.4,6,7
When LVEF is reported as an outcome measure, it
is important to know which technique is used as data
may not be interchangeable between methods, as each
will have various measurement errors and intrinsic
biases. To estimate the comparability of data between
methods, an approach is to measure LVEF in the same
subject by the two methods. This has been done when
comparing values using two techniques such as Echo
and MPS8–13; or when comparing either method with a
more invasive procedure such as ventriculogra-
phy.9,13,14 Comparability is generally gauged by calcu-
lating the significance of a correlation coefficient when
data pairs are plotted as a function of each other.
However, such a correlation analysis ignores any
systematic bias between the two methods: evident
when a linear regression of data pairs does not have
a slope of unity or the plot fails to approach the origin.
An alternative approach is a Bland–Altman analysis
whereby the difference in values by the two methods
is presented against the average of these values.15 This
detects any relative bias as well as emphasises the range
of differences in each data pair that a regression plot
displays less clearly.16 A few such analyses have com-
pared different methods to estimate LVEF8,12,14 and in
these both bias and a large variation of differences
within data pairs were evident, which suggested inter-
change of data between different methods was not jus-
tified. However, several confounders may contribute to
this negative conclusion that includes: the small
number of patients in most individual studies, as well
as either a preponderance of males or lack of informa-
tion about the gender mix. The latter may be of signif-
icance as measurements of LVEF by MPS show that a
threshold value below which the risk for myocardial
infarct (MI) or sudden cardiac death increases is differ-
ent for women (51%) and men (43%).17 By contrast,
there was no evidence of sex-dependent differences if
LVEF by echo was used as a prognostic indicator for
severe cardiac events.18,19 This study tested the hypoth-
esis, using a large data-set of patients, that
interchangeability of LVEF as measured by Echo and
MPS is different in men and women.
Methods
Patients, setting and study design
Patients were referred for assessment of cardiac symp-
toms, including chest pain and dyspnoea, and for those
undergoing cardiovascular surgery.4 A total of 1141
patients had LVEF measured both by resting MPS
and by Echo. Of these, 743 patients (Group 1: 404
men and 339 women) had separate examinations
within six months and their data were used for analysis.
A subset of these patients (Group 1A: n¼ 327; 181 men
and 246 women) had examinations within one month
and were additionally analysed (Figure 1). All exami-
nations were performed at a single centre between
30 November 2012 and 30 May 2017.
Anthropometric data and history of
cardiopulmonary conditions
Data recorded at the time of LVEF measurements were
collected including: weight and height for body mass
index (BMI) calculation; history of cardiopulmonary
conditions including MI; congestive heart failure
(CHF); atrial fibrillation (AF); hypertension; cardiac
interventions including coronary artery bypass graft
(CABG) and percutaneous coronary intervention
(PCI); chronic obstructive pulmonary disease
(COPD); and cardiac medications including beta-
blockers.
Myocardial perfusion scintigraphy
Data from rest MPS investigations, performed with the
injection of 99mTc-tetrofosmin (600–1000 MBq), were
used. Images were obtained using dual-head SPECT
cameras (Siemens Symbia S, Erlangen, Germany)4
and LVEF was determined from gated images as pre-
viously described.20
Echocardiography
Rest Echo data were obtained with a high-end two-
dimensional echocardiographic unit (Sonos 5500,
Andover, MA, US or Vingmed System V, Horten,
Norway). Images were acquired with standard para-
sternal, short-axis and apical views and LVEF was cal-
culated by the modified Simpson’s biplane disks
method.21 Analysis of images was performed by a car-
diologist independent from the radiologist who evalu-
ated the MPS measurements.
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Statistical methods
Linear regression was used to assess the correlation
between LVEF, measured either by MPS or Echo, by
generating a regression coefficient (r). Bland–Altman
analysis was performed by plotting and regressing
LVEF difference (MPS minus Echo) against average
LVEF (MPSþEcho2 ) to assess bias, trend in bias and 95%
limits of agreement ( 2SD of the mean of LVEF
difference) between the two techniques. LVEF differ-
ence was also regressed against age and BMI to assess
any influences from these factors. To determine effects
of cardiopulmonary conditions (see above), LVEF dif-
ference was compared between groups of patients with
a co-morbidity against those without using indepen-
dent t-test. Within-group (e.g. in men or in women)
differences in LVEF measured by the two methods
were assessed by paired t-tests.
Results
For Group 1 patients (n¼ 743, 45.6% women), mean
age (67.7 years) was the same in men and women
(Table 1). Echo was performed before MPS in more
patients (n¼ 508) than the alternative (n¼ 235), but
conclusions were similar if the two subsets were ana-
lysed separately, therefore data for the entire patient set
are presented. For Group 1A patients assessed within
one month apart (rapid subset) by both methods, age
was also similar between genders (n¼ 327, 44.6%
women) and Echo was performed before MPS in 191
and after in 136 patients.
Table 2 shows the distribution of co-morbidities
among men and women with obesity, AF and hyperten-
sion, MI, CHF, cardiac intervention, COPD and treat-
ment with beta-blockers. Table 3 shows that the LVEF
difference between MPS and Echo measured within
sixmonths apart was lower in men with MI, CHF, AF,
Figure 1. Numbers of patients who had MPS and Echo exami-
nations within six months (n¼ 743) and within one month
(n¼ 327) apart.
Table 1. Subject characteristics of patients who underwent cardiac assessment by MPS and Echo within six months apart (n¼ 743)





Group 1: MPS and Echo performed
within six months apart Mean SD Mean SD
Age (years) 67.7 12.3 67.7 11.7
BMI (kg/m2) 28.8 5.9 29.1 6.1
LVEF by MPS (%) 59.5 12.9 72.5 12.4
LVEF by Echo (%) 58.3 10.1 61.6 9.0
LVEF difference (MPS minus Echo), % 1.1 10.2 10.9 10.8
Average LVEF (MPSþ Echo)/2, % 58.9 10.4 67.0 9.4
Group 1A: MPS and Echo performed





Age (years) 68.8 12.1 66.4 12.1
BMI (kg/m2) 28.4 4.9 29.1 6.3
LVEF by MPS (%) 60.7 12.6 72.6 12.6
LVEF by Echo (%) 59.3 9.4 61.3 8.9
LVEF difference (MPS minus Echo), % 1.3 9.7 11.3 11.0
Average LVEF (MPSþ Echo)/2, % 60.0 10.0 66.9 9.4
Note: Bold characters indicate significant differences between groups.
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and treatment with beta-blockers compared to men with-
out these conditions, and higher in women of older age
and lower in women with CHF compared with younger
women or women without CHF, respectively. A similar
pattern was observed for LVEF difference measured by
the two techniques one month apart.
Significant relationships (all p< 0.001) were found
between LVEF measured by Echo and MPS in men
and women (Figure 2): for men r¼ 0.627 and
r¼ 0.644, Group 1 and Group 1A respectively; for
women r¼ 0.530 and r¼ 0.527, Group 1 and Group
1A, respectively. However, the slopes of the relation-
ship were less than unity in all cases, and the intercept
was significantly different from zero (Figure 2(a)
to (d)). Moreover, mean values of LVEF were signifi-
cantly greater by MPS compared to Echo in both men
(p¼ 0.028) and women (p< 0.001). For men, the mean
difference (MPS-Echo) was 1.1% or 1.3% for Groups 1
and 1A data. However, for women, the mean difference
was much higher; 10.9 and 11.3%, respectively.
Bland–Altman analysis was conducted showing that
among those who had MPS and Echo performed up
Table 2. Proportions of men and women with different underlying co-morbidities and treatment.
MPS and Echo performed within
six months apart (n¼ 743)
MPS and Echo performed within
one month apart (n¼ 327)
Men (%) Women (%) Men (%) Women (%)
BMI >30 kg/m2 31.9 38.1 32.9 36.4
AF 24.3 19.9 25.2 18.0
MI 36.1 13.4 29.4 7.2
CHF 18.8 6.2 14.1 6.5
Cardiac intervention 39.9 16.5 33.5 10.1
COPD 13.0 6.9 16.0 9.4
Hypertension 64.9 61.1 63.2 56.1
Beta-blockers 56.3 41.7 52.3 37.7
Table 3. Comparison of LVEF difference (MPS minus Echo) between patients with a condition against those without using inde-
pendent t-test.
Difference in ‘LVEF difference’ between group with co-morbidity
against group without co-morbidity
Men Women
Mean
difference (%) 95%CI p
Mean
difference (%) 95%CI p
Group 1: MPS and Echo performed within six months apart
Older minus younger age 1.5 0.5 to 3.5 0.141 2.3 0.2 to 4.8 0.036
BMI  30 kg/m2 minus BMI< 30 kg/m2 1.9 4.3 to 0.6 0.572 0.5 3.2 to 2.1 0.690
MI minus no-MI 2.4 4.6 to 0.2 0.031 3.2 6.7 to 0.2 0.068
CHF minus no-CHF 5.7 8.3 to 3.0 <0.001 9.7 14.5 to 4.9 < 0.001
AF minus no-AF 3.1 5.6 to 0.7 0.013 1.4 4.4 to 1.5 0.346
Cardiac intervention minus no-intervention 2.0 4.2 to 0.1 0.068 0.6 2.6 to 3.8 0.718
Hypertension minus no-hypertension 0.1 2.1 to 2.3 0.923 0.0 2.4 to 2.4 1.000
COPD minus no-COPD 0.3 2.9 to 3.4 0.862 2.4 2.7 to 6.6 0.404
Beta-blockers minus non-beta-blockers 3.4 5.5 to 1.2 0.002 1.4 3.6 to 1.0 0.242
Group 1A: MPS and Echo performed within one month apart
Older minus younger age 1.1 1.8 to 4.0 0.464 1.2 2.4 to 4.8 0.511
BMI 30 kg/m2 minus BMI< 30 kg/m2 1.6 5.2 to 2.0 0.384 0.2 4.3 to 4.0 0.931
MI minus no-MI 0.6 4.0 to 2.8 0.729 3.9 11.9 to 3.2 0.278
CHF minus no-CHF 6.1 10.5 to 1,7 0.007 12.2 19.4 to 5.1 0.001
AF minus no-AF 4.7 8.2 to 1.2 0.009 1.7 6.4 to 3.1 0.494
Cardiac intervention minus no-intervention 3.2 6.5 to 0.1 0.059 0.4 5.7 to 6.5 0.906
Hypertension minus no-hypertension 0.9 2.4 to 4.1 0.874 0.2 3.5 to 3.9 0.897
COPD minus no-COPD 1.4 5.7 to 2.8 0.507 2.3 8.6 to 4.0 0.471
Beta-blockers minus non-beta-blockers 2.6 5.8 to 0.5 0.104 1.8 5.6 to 2.1 0.364
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to sixmonths apart, the overall bias was þ1.1%
(19.3 to þ21.6) in men (Figure 3(a)) and þ10.9%
(10.7 to þ32.5) in women (Figure 3(b)). Difference
in LVEF correlated with average LVEF in men
(r¼ 0.361, p< 0.001) and women (r¼ 0.392,
p< 0.001) but not with age. A one-sample t-test
showed LVEF difference diverged from zero only
marginally in men (mean difference¼þ1.1, 95%CI
¼þ0.1 to þ2.1, p¼ 0.028) but more in women
(þ10.9, þ9.8 to þ12.1, p< 0.001).
The overall bias (mean LVEF difference) was
þ1.3% (95% limits of agreement: 18.1 to þ20.7) in
men (Figure 3(c)) and þ11.3% (10.6 to þ33.2) in
women (Figure 3(d)). LVEF difference correlated
with average LVEF in men (r¼ 0.305, p< 0.001) and
women (r¼ 0.361, p< 0.001), and with age in women
only (r¼ 0.117, p¼ 0.031). LVEF difference diverged
from zero only marginally in men (mean difference¼
þ1.0, 95%CI¼þ0.2 to þ1.9, p¼ 0.015) but more
markedly in women (mean difference¼þ11.1, 95%
CI¼þ10.2 to þ12.0, p< 0.001).
Linear stepwise multiple regression analysis was
conducted to regress LVEF differences (dependent var-
iable) on average LVEF, sex, age and co-morbidities
(independent variables). All independent variables were
entered simultaneously in the regression model using a
forward selection method: only average LVEF, sex and
age were retained as significant independent variables
in the final model, while co-morbidities including obe-
sity, AF, MI, CHF, cardiac intervention, COPD,
hypertension and beta-blocker treatment were elimi-
nated. For group 1: mean difference (MPS-Echo)¼
0.398Average LVEF – 6.0 sex (0 for women, 1
for men)þ 0.122Age – 24.3 (coefficient of determi-
nation (r2)¼ 28%, p< 0.001); for group 1A: mean dif-
ference (MPS-Echo)¼ 0.449Average LVEF – 6.2
sex (0 for women, 1 for men)þ 0.135Age – 28.3
(r2¼ 31%, p< 0.001).
Figure 2. Scatter plot for the relationship between LVEF measured by MPS and by Echo measured within six months (a) and within
one month apart (b) in men and within six months (c) and within one month apart (d) in women. Solid line indicates regression line of
best fit and dashed line indicates line of unity. Intercepts were significantly different from origin (indicated in brackets).
Jaker et al. 5
Discussion
Summary
The present study found a marked systematic bias in
LVEF measured by MPS and Echo in women com-
pared to that in men, with wide limits of agreement
between these two techniques. These results suggest
that LVEF measured by different methods may not
be used interchangeably in either clinical or research
settings. In particular, our observations of sex differ-
ences in LVEF estimated by Echo and especially by
MPS and have not been previously reported. These
findings are highly valuable when interpreting results
by different methods and would have profound impli-
cations on diagnosis, prognostication of cardiac out-
comes and therapy. These sex differences may also
explain the observation of sex differences in LVEF as
prognostic indicators of myocardial infarction and car-
diac death.17
There are a number of published papers assessing
relationships between LVEF measured by MPS and
Echo using a linear regression technique to provide cor-
relation coefficients,8,9,11,12,22 However, only a few of
these studies assessed agreement between methods using
Bland–Altman technique.8,12 Scatter plots of LVEF mea-
sured by MPS or by Echo in our study confirm the defi-
ciency of a correlation approach; the linear regression
line deviated from origin indicating the presence of a
bias. Furthermore, most previous studies recruited
small numbers of participants (between 30 and 80) with
unknown sex balance or preponderantly men. Our anal-
yses of 743 participants divided approximately equally
between men and women are, to our knowledge, the
largest of its kind, providing a greater level of confidence
Figure 3. Bland and Altman plot between LVEF difference against mean LVEF to assess bias and agreement between LVEF measured
by MPS and Echo within sixmonths apart (a: men and b: women) or within onemonth apart (c: men and d: women). Solid line
indicates the mean of overall bias between methods (MPS minus Echo) dashed lines indicate 95% limits of agreement.
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in our findings. Findings from our study suggest that
while a good correlation exists between LVEF measured
byMPS or Echo, there is a significant bias engendered by
one method compared to the other, especially when
measurements were made on women.
Both MPS and Echo are techniques used in clinical
setting and neither is considered as a ‘reference
method’. Therefore, it is not certain if one method
overestimates or the other underestimates the ‘true’
LVEF value. The observation of correlations between
LVEF differences and average LVEF suggests a rela-
tively lower value by Echo in patients with lower LVEF
and relatively higher value by MPS in patients with
higher LVEF. Joffe et al.14 examined LVEF measured
by Echo and ventriculography in 741 men and women.
Both sexes were analysed together and it was found
that the 95% limits of agreement (þ20% and 20%)
of LVEF measured by Echo and ventriculography were
in a similar range as those found in our study. We
found that sex differences between MPS and Echo to
be remarkably similar to differences in LVEF thresh-
olds performed by MPS in the prediction of myocardial
infarct and cardiac mortality.17
Stepwise regression analysis revealed that LVEF
values measured by MPS were increasingly higher
than those by Echo in those with higher LVEF meas-
urements or older age and these values were lower in
men than in women, while obesity, MI, AF, CHF,
COPD, hypertension and beta-blockers were not relat-
ed to trends in bias. It would be of interest to examine
the agreement of these two methods in patients with
abnormal ejection fraction, but there were not enough
numbers in the present study with such a group of
patients.
Our data however cannot completely explain sex
differences between method agreement on LVEF mea-
surement but men with MI, CHF, AF and medications
such as beta-blockers and women of older age and
CHF had significant influences on LVEF difference
between MPS and Echo. It is therefore important to
recalibrate either or both MPS and Echo and take
underlying co-morbidities into account to provide con-
sistency between methods, but this would require the
use of a standard method for cross-reference for these
two techniques. A potential bias not examined in our
study is that the acoustic window for Echo in women
can be suboptimal. Women also generally have a rela-
tively larger amount of subcutaneous adipose tissue for
a given BMI than men23 which may have some bearing
on Echo measurement. Because of its low cost and
operational ease, Echo is widely used for assessing
LVEF. However, this method has a number of draw-
backs because it is operator-dependent and relies on
geometric assumptions such that the measurements
can be erroneous in patients with ventricular defects
including those with dilated, remodelled ventricles.24,25
MPS, which is increasingly used for cardiac stratifica-
tion, also computes LVEF. MPS also suffers limita-
tions, including high cost, involving radiation
exposure (especially for patients undergoing repeat
testing),26 requirement of highly trained specialists
and its unreliability in the presence of arrhythmias or
tachycardia.9,24
Strengths and limitations of the study
The strengths of the present study lie in its large num-
bers of subjects. Together with the use of Bland–
Altman analysis, we are confident that our findings
are robust. The present study examined a wide range
of measurements that may have some bearing on out-
comes of the results such as BMI, drug therapy and co-
morbidities. Ideally, the two methods should be done
within a short time of each other because any differ-
ences could be due to changes of cardiac function. Joffe
et al.14 found that an interval of up to seven days,
between LVEF measured by Echo and by left ventri-
culography made little contribution to variation in test
results. This study analysed MPS and Echo data when
measured within six months apart and found very sim-
ilar data when measured only one month apart, sug-
gesting no significant population deterioration over this
time-frame.
Conclusions
Caution should be taken when interpreting LVEF mea-
sured by MPS and Echo, especially in women, due to
their wide limits of agreement and systematic bias.
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